136 related articles for article (PubMed ID: 30577887)
1. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection.
Patel KP; Ruiz-Cordero R; Chen W; Routbort MJ; Floyd K; Rodriguez S; Galbincea J; Barkoh BA; Hatfield D; Khogeer H; Kanagal-Shamanna R; Yin CC; Zuo Z; Loghavi S; Ok CY; DiNardo CD; Luthra R; Medeiros LJ
J Mol Diagn; 2019 Jan; 21(1):89-98. PubMed ID: 30577887
[TBL] [Abstract][Full Text] [Related]
2. Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing.
Hiemenz MC; Kadauke S; Lieberman DB; Roth DB; Zhao J; Watt CD; Daber RD; Morrissette JJ
PLoS One; 2016; 11(4):e0152851. PubMed ID: 27043212
[TBL] [Abstract][Full Text] [Related]
3. Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification.
de Noronha TR; Mitne-Neto M; Chauffaille ML
J Investig Med; 2017 Dec; 65(8):1155-1158. PubMed ID: 28923882
[TBL] [Abstract][Full Text] [Related]
4. A robust and cost-effective approach to sequence and analyze complete genomes of small RNA viruses.
Dimitrov KM; Sharma P; Volkening JD; Goraichuk IV; Wajid A; Rehmani SF; Basharat A; Shittu I; Joannis TM; Miller PJ; Afonso CL
Virol J; 2017 Apr; 14(1):72. PubMed ID: 28388925
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
[TBL] [Abstract][Full Text] [Related]
6. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
7. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.
Allegretti M; Fabi A; Buglioni S; Martayan A; Conti L; Pescarmona E; Ciliberto G; Giacomini P
J Exp Clin Cancer Res; 2018 Mar; 37(1):47. PubMed ID: 29506529
[TBL] [Abstract][Full Text] [Related]
8. Next generation sequencing in hematolymphoid neoplasia.
Kuo FC
Semin Hematol; 2019 Jan; 56(1):2-6. PubMed ID: 30573040
[TBL] [Abstract][Full Text] [Related]
9. Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels.
Kerkhof J; Schenkel LC; Reilly J; McRobbie S; Aref-Eshghi E; Stuart A; Rupar CA; Adams P; Hegele RA; Lin H; Rodenhiser D; Knoll J; Ainsworth PJ; Sadikovic B
J Mol Diagn; 2017 Nov; 19(6):905-920. PubMed ID: 28818680
[TBL] [Abstract][Full Text] [Related]
10. Lake Louise mutation detection meeting 2013: clinical translation of next-generation sequencing requires optimization of workflows and interpretation of variants.
Smith A; Boycott KM; Jarinova O
Hum Mutat; 2014 Feb; 35(2):265-9. PubMed ID: 24282140
[TBL] [Abstract][Full Text] [Related]
11. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of amplicon-based next-generation sequencing in cancer.
Chang F; Li MM
Cancer Genet; 2013 Dec; 206(12):413-9. PubMed ID: 24332266
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
14. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of targeted next-generation sequencing for inherited disorders.
Yohe S; Hauge A; Bunjer K; Kemmer T; Bower M; Schomaker M; Onsongo G; Wilson J; Erdmann J; Zhou Y; Deshpande A; Spears MD; Beckman K; Silverstein KA; Thyagarajan B
Arch Pathol Lab Med; 2015 Feb; 139(2):204-10. PubMed ID: 25611102
[TBL] [Abstract][Full Text] [Related]
16. Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease.
Marjanovic I; Kostic J; Stanic B; Pejanovic N; Lucic B; Karan-Djurasevic T; Janic D; Dokmanovic L; Jankovic S; Vukovic NS; Tomin D; Perisic O; Rakocevic G; Popovic M; Pavlovic S; Tosic N
Tumour Biol; 2016 Oct; 37(10):13391-13401. PubMed ID: 27460089
[TBL] [Abstract][Full Text] [Related]
17. Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.
Schenkel LC; Kerkhof J; Stuart A; Reilly J; Eng B; Woodside C; Levstik A; Howlett CJ; Rupar AC; Knoll JHM; Ainsworth P; Waye JS; Sadikovic B
J Mol Diagn; 2016 Sep; 18(5):657-667. PubMed ID: 27376475
[TBL] [Abstract][Full Text] [Related]
18. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.
Aguilera-Diaz A; Vazquez I; Ariceta B; Mañú A; Blasco-Iturri Z; Palomino-Echeverría S; Larrayoz MJ; García-Sanz R; Prieto-Conde MI; Del Carmen Chillón M; Alfonso-Pierola A; Prosper F; Fernandez-Mercado M; Calasanz MJ
PLoS One; 2020; 15(1):e0227986. PubMed ID: 31978184
[TBL] [Abstract][Full Text] [Related]
20. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
